The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

MO Supreme Court Upholds $38 Million Verdict in Depakote Birth Defect Trial

Posted on October 13, 2017 by Larry Bodine

Internally, Abbott referring to Depakote as a “dirty drug.”

The Supreme Court of Missouri has upheld a $38 million award to a Minnesota woman who was born with spina bifida and other birth defects after her mother took Depakote while she was pregnant.

Abbot Laboratories makes Depakote, an anti-epilepsy drug. Plaintiff Maddison Schmidt proved that the label for Depakote, which company documents referred to as a “dirty drug,” failed to warn adequately of serious dangers of birth defects.

The Supreme Court said that “there was evidence Abbott was aware there were studies indicating Depakote was much more dangerous in terms of birth defects than its label suggested. In addition, there was evidence presented that, despite this knowledge, Abbott conducted no independent research or studies of its own to evaluate Depakote’s risks for birth defects.

Marketing a defective drug

There was evidence showing Abbott instead spent $50 million to $100 million per year marketing Depakote, sought to “squeeze every dollar and every [prescription for Depakote] out of the market.”

The Supreme Court shot down Abbott’s argument that it was prejudiced because the trial was in the City of St. Louis Circuit Court. Abbott claimed without evidence the court was biased.

Depakote’s label stated: there was clinical literature indicating “the use of antiepileptic drugs during pregnancy results in an increased incidence of birth defects;” Depakote had “a possible similar association” as other antiepileptic drugs to birth defects; and the Centers for Disease Control estimated the risk of pregnant women exposed to Depakote having children with spina bifida was only 1 or 2 percent.

Schmidt, however, presented evidence Abbott was aware of multiple studies concluding: (1) Depakote posed a considerably higher risk of overall birth defects than other antiepileptic drugs, and should be avoided by women of childbearing potential unless all other alternatives had been tried and failed; (2) the overall risk of birth defects was 10 percent or even greater; (3) the risk of spina bifida was significantly higher than 1 or 2 percent; and (4) the risk of spina bifida amounted to a twentyfold increased risk compared with the background rate in the general population.

 

Posted in Blog, Product Liability

Comments are closed.

News Categories

Read about other Top Jury Verdicts

Walgreens Agrees to a $105 Million Shareholders Settlement

Walgreens Agrees to a $105 Million Shareholders Settlement

Walgreens Boots Alliance Inc (WBA.O) agreed to pay $105 million to settle a long-running class-action lawsuit accus[Read More...]
A Military Couple Reaches a $15 Million Settlement With Tripler Hospital Over Botched Delivery

A Military Couple Reaches a $15 Million Settlement With Tripler Hospital Over Botched Delivery

A federal judge in Hawaii has approved a $15 million settlement for an Army couple whose son suffered brain damage from lack [Read More...]
Defrauded College Students Will Have $6 Billion Forgiven in a New Settlement

Defrauded College Students Will Have $6 Billion Forgiven in a New Settlement

The Biden administration has agreed to cancel $6 billion in student loans for about 200,000 former students who say they were[Read More...]
An Iowa City Settles Lawsuit Over a Deadly Police Shooting For $5 Million

An Iowa City Settles Lawsuit Over a Deadly Police Shooting For $5 Million

Burlington, Iowa, has agreed to pay $5 million to settle a wrongful death lawsuit brought by the mother of a man who was shot[Read More...]
Co-Owners File a $695 Million Lawsuit Against Georgia Power Over a Contract Dispute

Co-Owners File a $695 Million Lawsuit Against Georgia Power Over a Contract Dispute

The owners of a majority share of a nuclear power plant being expanded in Georgia are suing lead owner Georgia Power Co., cla[Read More...]

#LegalNews

@@TheNTLtop100

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.